Cambridge, United Kingdom and Boston, Massachusetts — September 3, 2025 — Leads & Copy — CellCentric has initiated dosing in new cohorts evaluating inobrodib in combination with B-cell maturation antigen (BCMA) directed CD3 T-cell engagers, according to a press release. The ongoing Phase 1/2 clinical trial is for the treatment of patients with relapsed/refractory myeloma and has now initiated new dosing cohorts evaluating inobrodib in combination with teclistamab-cqyv and inobrodib in combination with elranatamab-bcmm (NCT0406857).
Approximately 40 patients are expected to receive the combination of inobrodib with either bispecific agent. Initial safety evaluation data is expected by the end of 2025. Other treatment regimens are also being assessed as part of this study.
“We’re excited to build upon the positive data presented at ASH 2024, which demonstrated encouraging clinical activity for inobrodib both as a monotherapy and in combination. Based on these results, we are rapidly advancing inobrodib across several treatment settings in multiple myeloma,” said CellCentric’s CEO, Will West. “As a first-in-class agent with a favorable safety profile, we believe inobrodib has broad therapeutic potential, including in combination with a range of other therapies such as bispecific antibodies that have transformed the multiple myeloma treatment landscape in recent years.”
In April 2025, the company opened a new office in the Boston area, expanding its U.S. footprint and development capacity. In May 2025, it secured a $120 million Series C funding round, co-led by RA Capital Management and Forbion, to accelerate registration trials for inobrodib and evaluate bispecific antibody combinations. This progress has been complemented by expansion across all levels of the team, spanning clinical operations, regulatory and corporate functions.
Inobrodib is a first-in-class potential new treatment for people with cancer, and multiple myeloma in particular. It is a small molecule drug that targets p300/CBP, lowering the expression of key cancer drivers, including MYC and IRF4. It has been evaluated in over 400 patients to date and has a favorable safety and tolerability profile. Clinical activity has been seen in multiple settings, both solid tumor and hematologic malignancies. Delivered as an oral capsule, it is easy for patients to take and can be used at home without the need for intensive monitoring. Its differentiated profile may broaden use among patients who cannot tolerate or access other treatments, while its ease of administration could reduce healthcare system burden relative to more complex therapies.
CellCentric maintains development and commercial rights to inobrodib and is free to expand the program in combination with other agents.
For more information, please contact: IR@cellcentric.com
Source: CellCentric
